Cargando…

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy

Currently, breast cancer patients are classified uniquely according to the expression level of hormone receptors, and human epidermal growth factor receptor 2 (HER2). This coarse classification is insufficient to capture the phenotypic complexity and heterogeneity of the disease. A methodology was d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peckys, Diana B., Gaa, Daniel, de Jonge, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623301/ https://www.ncbi.nlm.nih.gov/pubmed/34831465 http://dx.doi.org/10.3390/cells10113244

Ejemplares similares

Local variations of HER2 dimerization in breast cancer cells discovered by correlative fluorescence and liquid electron microscopy
por: Peckys, Diana B., et al.
Publicado: (2015)

Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers
por: Peckys, Diana B., et al.
Publicado: (2017)

EGFR Expression in HER2-Driven Breast Cancer Cells
por: Weinberg, Florian, et al.
Publicado: (2020)

Visualisation of HER2 homodimers in single cells from HER2 overexpressing primary formalin fixed paraffin embedded tumour tissue
por: Peckys, Diana B., et al.
Publicado: (2019)

Structure and dynamics of the EGFR/HER2 heterodimer
por: Bai, Xue, et al.
Publicado: (2023)

Visualizing Gold Nanoparticle Uptake in Live Cells with Liquid Scanning Transmission Electron Microscopy
por: Peckys, Diana B., et al.
Publicado: (2011)

HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial
por: Barber, Paul R, et al.
Publicado: (2019)

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
por: Choi, Byoungsan, et al.
Publicado: (2020)

Mathematical modeling of drug-induced receptor internalization in the HER2-positive SKBR3 breast cancer cell-line
por: Fehling-Kaschek, Mirjam, et al.
Publicado: (2019)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
por: Zhao, Jun, et al.
Publicado: (2021)

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
por: Peckys, Diana B., et al.
Publicado: (2015)

Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer
por: Zhang, Tongtong, et al.
Publicado: (2016)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Epidermal growth factor receptor subunit locations determined in hydrated cells with environmental scanning electron microscopy
por: Peckys, Diana B., et al.
Publicado: (2013)

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
por: Shin, Jung Won, et al.
Publicado: (2019)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Corrigendum: Epidermal growth factor receptor subunit locations determined in hydrated cells with environmental scanning electron microscopy
por: Peckys, Diana B., et al.
Publicado: (2015)

Nanoscale Imaging of Whole Cells Using a Liquid Enclosure and a Scanning Transmission Electron Microscope
por: Peckys, Diana B., et al.
Publicado: (2009)

Supra-Molecular Assemblies of ORAI1 at Rest Precede Local Accumulation into Puncta after Activation
por: Peckys, Diana B., et al.
Publicado: (2021)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
por: Bahleda, Rastislav, et al.
Publicado: (2018)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Towards comprehensive characterization of HER2 overexpression
por: Berezov, Alan, et al.
Publicado: (2006)

MicroRNA and HER2-overexpressing Cancer
por: Wang, Shizhen Emily, et al.
Publicado: (2013)

Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2
por: Tobin, Steven J., et al.
Publicado: (2018)

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
por: Weitsman, Gregory, et al.
Publicado: (2016)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2
por: Kim, H, et al.
Publicado: (2016)

mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer
por: Wada, Ryuichi, et al.
Publicado: (2016)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
por: Batalha, Sofia, et al.
Publicado: (2023)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eov8cb0qipl6au6vdf9b9906a6